Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | CCR8 | P51685 | 2/20 | 0.37 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30164264 | 1.00 | NOS3 (0.46) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL1193387 | 0.98 | NOS3 (0.45) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL29861810 | 0.98 | NOS3 (0.45) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL873234 | 0.79 | NOS3 (0.48) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL29384905 | 0.79 | NOS3 (0.48) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL2112705 | 0.78 | S1PR1 (0.39) | AGBL2L3MBTL1KDM4EMAPK1KMT2A | |
| SCHEMBL16039165 | 0.78 | CCR1 (0.34) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL29636159 | 0.78 | CCR1 (0.34) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL13196217 | 0.77 | NOS3 (0.46) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL17248011 | 0.77 | NOS3 (0.46) | NOS3NOS1NOS2HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0240158-B1 | BENZIMIDAZOLE DERIVATIVES | TOKYO TANABE COMPANY LIMITED (JP) | 1991-04-03 | — | — | EP | claimed |
| CN-118638100-A | CXCR4/HDAC dual inhibitor and preparation and application thereof | 杭州师范大学 | 2024-09-13 | — | — | CN | disclosed |
| CN-117720518-B | Benzimidazole compound, preparation method thereof, pharmaceutical composition and application | 江苏海洋大学 | 2024-08-13 | — | — | CN | disclosed |
| CN-117720518-A | Benzimidazole compound, preparation method thereof, pharmaceutical composition and application | 江苏海洋大学 | 2024-03-19 | — | — | CN | disclosed |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | AUTOIMMUNE PHARMA LLC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| US-9850237-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| WO-2007056220-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056228-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (GB) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056021-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| CN-1882589-A | Novel heterocyclic compounds as HSP 90-inhibitors | CONFORMA THERAPEUTICS CORP (US) | 2006-12-20 | — | — | CN | disclosed |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | NEUROGEN CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-0254588-B1 | Imidazo[4,5-b] pyridine compounds, process for preparing same and pharmaceutical compositions containing same | TOKYO TANABE COMPANY LIMITED (JP) | 1992-01-15 | — | — | EP | disclosed |
| US-4808596-A | STORAGE STABLE, ANTIULCER AGENTS | TOKYO TANABE COMPANY, LTD. (JP) | 1989-02-28 | — | — | US | disclosed |
| EP-0254588-A1 | Imidazo[4,5-b] pyridine compounds, process for preparing same and pharmaceutical compositions containing same | TOKYO TANABE COMPANY LIMITED (JP) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | NOS3 1389/4885NOS1 2729/4885NOS2 2918/4885 |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | NOS3 1178/4885NOS1 710/4885NOS2 1002/4885 |
| US-10316028-B2 | Orexin receptor antagonists | HCRTR2, HCRTR1, NPY4R | NOS3 1389/4885NOS1 2729/4885NOS2 2918/4885 |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | GABRP, GABBR1, GABRA1 | NOS3 3411/4885NOS1 3792/4885NOS2 3753/4885 |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | NOS3 1389/4885NOS1 2729/4885NOS2 2918/4885 |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | LTB4R, LTC4S, LTB4R2 | NOS3 144/4885NOS1 181/4885NOS2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.